Icotinib Hydrochloride (BPI-2009H), or Icotinib, is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Icotinib is clinically used as first-line monotherapy in patients with non-small-cell lung cancer with somatic EGFR mutations. Currently, it is solely approved and marketed in China.
